
Tianjin Medical Journal ›› 2022, Vol. 50 ›› Issue (10): 1009-1013.doi: 10.11958/20220599
• Cell and Molecular Biology • Next Articles
LIN Haipeng, DANG Xuhong, ZUO Yahui
Received:2022-04-22
Revised:2022-06-09
Published:2022-10-15
Online:2022-10-20
LIN Haipeng, DANG Xuhong, ZUO Yahui. Effects of substance P on the secretory function and the expression of endogenous VEGF, bFGF and PDGF in radiation-injured skin fibroblasts[J]. Tianjin Medical Journal, 2022, 50(10): 1009-1013.
CLC Number:
| 基因名称 | 引物序列(5'→3') | 产物大小(bp) |
|---|---|---|
| VEGF | 上游:CGAGACCCTGGTGGACATCTT | 180 |
| 下游:TGGCCTTGGTGAGGTTTGATC | ||
| bFGF | 上游:AGAAGAGCGACCCTCACATCA | 226 |
| 下游:CGTTTCAGTGCCACATACCAA | ||
| PDGF | 上游:ACCAGGACGGTCATTTACGA | 136 |
| 下游:AGGGCTGGCACTTGACACT | ||
| GAPDH | 上游:TGGGTGTGAACCATGAGAAGT | 126 |
| 下游:TGAGTCCTTCCACGATACCAA |
Tab. 1 Design of real-time fluorescence quantitative PCR primers
| 基因名称 | 引物序列(5'→3') | 产物大小(bp) |
|---|---|---|
| VEGF | 上游:CGAGACCCTGGTGGACATCTT | 180 |
| 下游:TGGCCTTGGTGAGGTTTGATC | ||
| bFGF | 上游:AGAAGAGCGACCCTCACATCA | 226 |
| 下游:CGTTTCAGTGCCACATACCAA | ||
| PDGF | 上游:ACCAGGACGGTCATTTACGA | 136 |
| 下游:AGGGCTGGCACTTGACACT | ||
| GAPDH | 上游:TGGGTGTGAACCATGAGAAGT | 126 |
| 下游:TGAGTCCTTCCACGATACCAA |
| 组别 | Col-Ⅰ (μg/L) | Col-Ⅲ (μg/L) | Col-Ⅰ/ Col-Ⅲ | CGRP (ng/L) |
|---|---|---|---|---|
| 0 Gy组 | 14.34±0.25 | 31.50±0.69 | 0.46±0.02 | 52.48±2.04 |
| 2 Gy组 | 20.50±0.19a | 30.14±0.35 | 0.68±0.01a | 53.07±3.50 |
| 6 Gy组 | 19.31±0.51a | 32.52±1.18 | 0.59±0.03a | 61.48±1.86a |
| 12 Gy组 | 21.07±0.84a | 33.37±0.74a | 0.63±0.02a | 99.91±4.94a |
| 18 Gy组 | 26.33±0.63a | 33.50±0.74a | 0.79±0.03a | 103.80±2.82a |
| 0 Gy+SP组 | 21.86±0.93a | 28.16±1.26a | 0.78±0.01a | 62.57±4.17a |
| 2 Gy+SP组 | 18.22±0.63b | 31.97±0.57b | 0.57±0.01b | 76.89±4.11b |
| 6 Gy+SP组 | 16.10±0.57c | 33.35±1.01 | 0.48±0.03c | 98.92±2.78c |
| 12 Gy+SP组 | 23.31±1.25d | 42.24±1.15d | 0.55±0.02d | 102.29±3.64 |
| 18 Gy+SP组 | 25.07±0.99 | 41.37±0.74e | 0.61±0.02e | 108.88±3.13 |
| F | 76.684** | 77.852** | 80.440** | 135.039** |
Tab. 2 Comparison of expression levels of Col-Ⅰ, Col-Ⅲ, Col-Ⅰ/Col-Ⅲ and CGRP between different culture medium groups
| 组别 | Col-Ⅰ (μg/L) | Col-Ⅲ (μg/L) | Col-Ⅰ/ Col-Ⅲ | CGRP (ng/L) |
|---|---|---|---|---|
| 0 Gy组 | 14.34±0.25 | 31.50±0.69 | 0.46±0.02 | 52.48±2.04 |
| 2 Gy组 | 20.50±0.19a | 30.14±0.35 | 0.68±0.01a | 53.07±3.50 |
| 6 Gy组 | 19.31±0.51a | 32.52±1.18 | 0.59±0.03a | 61.48±1.86a |
| 12 Gy组 | 21.07±0.84a | 33.37±0.74a | 0.63±0.02a | 99.91±4.94a |
| 18 Gy组 | 26.33±0.63a | 33.50±0.74a | 0.79±0.03a | 103.80±2.82a |
| 0 Gy+SP组 | 21.86±0.93a | 28.16±1.26a | 0.78±0.01a | 62.57±4.17a |
| 2 Gy+SP组 | 18.22±0.63b | 31.97±0.57b | 0.57±0.01b | 76.89±4.11b |
| 6 Gy+SP组 | 16.10±0.57c | 33.35±1.01 | 0.48±0.03c | 98.92±2.78c |
| 12 Gy+SP组 | 23.31±1.25d | 42.24±1.15d | 0.55±0.02d | 102.29±3.64 |
| 18 Gy+SP组 | 25.07±0.99 | 41.37±0.74e | 0.61±0.02e | 108.88±3.13 |
| F | 76.684** | 77.852** | 80.440** | 135.039** |
| 组别 | Col-Ⅰ (μg/L) | Col-Ⅲ (μg/L) | Col-Ⅰ/ Col-Ⅲ | CGRP (ng/L) |
|---|---|---|---|---|
| 0 Gy组 | 38.78±0.53 | 73.59±0.66 | 0.53±0.01 | 26.56±0.61 |
| 2 Gy组 | 39.10±0.62 | 72.29±0.90 | 0.54±0.01 | 33.53±0.71a |
| 6 Gy组 | 42.98±1.28a | 78.70±1.94a | 0.55±0.00 | 31.10±0.58a |
| 12 Gy组 | 39.69±1.12 | 72.84±0.62 | 0.54±0.02 | 32.55±0.73a |
| 18 Gy组 | 43.86±0.71a | 78.05±1.83a | 0.56±0.01a | 31.48±0.09a |
| 0 Gy+SP组 | 37.81±0.49 | 72.13±0.90 | 0.52±0.01 | 29.52±1.25a |
| 2 Gy+SP组 | 33.64±0.42b | 65.40±1.88b | 0.51±0.02b | 28.81±0.41b |
| 6 Gy+SP组 | 37.25±0.31c | 79.14±1.70 | 0.47±0.01c | 32.70±0.96c |
| 12 Gy+SP组 | 38.19±0.37d | 68.44±0.77d | 0.56±0.01 | 31.07±0.95d |
| 18 Gy+SP组 | 37.19±0.44e | 70.83±0.84e | 0.53±0.00e | 38.15±0.58e |
| F | 52.361** | 34.876** | 14.151** | 51.309** |
Tab. 3 Comparison of the expression levels of endogenous Col-Ⅰ, Col-Ⅲ, Col-Ⅰ/Col-Ⅲ and CGRP between the ten groups
| 组别 | Col-Ⅰ (μg/L) | Col-Ⅲ (μg/L) | Col-Ⅰ/ Col-Ⅲ | CGRP (ng/L) |
|---|---|---|---|---|
| 0 Gy组 | 38.78±0.53 | 73.59±0.66 | 0.53±0.01 | 26.56±0.61 |
| 2 Gy组 | 39.10±0.62 | 72.29±0.90 | 0.54±0.01 | 33.53±0.71a |
| 6 Gy组 | 42.98±1.28a | 78.70±1.94a | 0.55±0.00 | 31.10±0.58a |
| 12 Gy组 | 39.69±1.12 | 72.84±0.62 | 0.54±0.02 | 32.55±0.73a |
| 18 Gy组 | 43.86±0.71a | 78.05±1.83a | 0.56±0.01a | 31.48±0.09a |
| 0 Gy+SP组 | 37.81±0.49 | 72.13±0.90 | 0.52±0.01 | 29.52±1.25a |
| 2 Gy+SP组 | 33.64±0.42b | 65.40±1.88b | 0.51±0.02b | 28.81±0.41b |
| 6 Gy+SP组 | 37.25±0.31c | 79.14±1.70 | 0.47±0.01c | 32.70±0.96c |
| 12 Gy+SP组 | 38.19±0.37d | 68.44±0.77d | 0.56±0.01 | 31.07±0.95d |
| 18 Gy+SP组 | 37.19±0.44e | 70.83±0.84e | 0.53±0.00e | 38.15±0.58e |
| F | 52.361** | 34.876** | 14.151** | 51.309** |
| 组别 | VEGF mRNA | bFGF mRNA | PDGF mRNA |
|---|---|---|---|
| 0 Gy组 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 |
| 2 Gy组 | 0.75±0.04a | 1.12±0.11 | 1.31±0.06 |
| 6 Gy组 | 1.13±0.10 | 1.70±0.44a | 1.62±0.16a |
| 12 Gy组 | 1.09±0.12 | 1.51±0.28a | 1.80±0.20a |
| 18 Gy组 | 1.03±0.03 | 1.65±0.33a | 1.90±0.09a |
| 0 Gy+SP组 | 1.64±0.16a | 1.55±0.15a | 1.57±0.14a |
| 2 Gy+SP组 | 1.28±0.04b | 1.65±0.09b | 1.57±0.17 |
| 6 Gy+SP组 | 0.86±0.04c | 1.55±0.39 | 1.54±0.37 |
| 12 Gy+SP组 | 2.31±0.01d | 1.98±0.04d | 2.45±0.45d |
| 18 Gy+SP组 | 2.14±0.22e | 2.62±0.32e | 2.42±0.27e |
| F | 81.916** | 8.663** | 11.405** |
Tab. 4 Comparison of mRNA expression levels of VEGF, bFGF and PDGF between the ten groups
| 组别 | VEGF mRNA | bFGF mRNA | PDGF mRNA |
|---|---|---|---|
| 0 Gy组 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 |
| 2 Gy组 | 0.75±0.04a | 1.12±0.11 | 1.31±0.06 |
| 6 Gy组 | 1.13±0.10 | 1.70±0.44a | 1.62±0.16a |
| 12 Gy组 | 1.09±0.12 | 1.51±0.28a | 1.80±0.20a |
| 18 Gy组 | 1.03±0.03 | 1.65±0.33a | 1.90±0.09a |
| 0 Gy+SP组 | 1.64±0.16a | 1.55±0.15a | 1.57±0.14a |
| 2 Gy+SP组 | 1.28±0.04b | 1.65±0.09b | 1.57±0.17 |
| 6 Gy+SP组 | 0.86±0.04c | 1.55±0.39 | 1.54±0.37 |
| 12 Gy+SP组 | 2.31±0.01d | 1.98±0.04d | 2.45±0.45d |
| 18 Gy+SP组 | 2.14±0.22e | 2.62±0.32e | 2.42±0.27e |
| F | 81.916** | 8.663** | 11.405** |
| 组别 | VEGF | bFGF | PDGF |
|---|---|---|---|
| 0 Gy组 | 788.84±41.15 | 24.92±0.28 | 12.02±0.21 |
| 2 Gy组 | 856.82±24.47a | 26.90±0.59a | 12.50±0.40a |
| 6 Gy组 | 954.71±23.71a | 24.75±0.28 | 11.74±0.19 |
| 12 Gy组 | 1 090.68±15.14a | 25.93±0.27a | 12.18±0.22 |
| 18 Gy组 | 1 140.53±24.67a | 26.92±0.94a | 12.66±0.32a |
| 0 Gy+SP组 | 1 100.65±29.08a | 19.77±0.34a | 12.23±0.22 |
| 2 Gy+SP组 | 1 174.97±21.75b | 20.34±0.34b | 12.83±0.30 |
| 6 Gy+SP组 | 1 065.30±40.36c | 25.33±0.34 | 11.85±0.21 |
| 12 Gy+SP组 | 1 285.55±21.81d | 22.42±0.22d | 13.09±0.18d |
| 18 Gy+SP组 | 1 317.28±26.13e | 27.64±0.36 | 14.78±0.21e |
| F | 112.077** | 114.822** | 36.113** |
Tab. 5 Comparison of protein expression levels of VEGF, bFGF and PDGF between the ten groups
| 组别 | VEGF | bFGF | PDGF |
|---|---|---|---|
| 0 Gy组 | 788.84±41.15 | 24.92±0.28 | 12.02±0.21 |
| 2 Gy组 | 856.82±24.47a | 26.90±0.59a | 12.50±0.40a |
| 6 Gy组 | 954.71±23.71a | 24.75±0.28 | 11.74±0.19 |
| 12 Gy组 | 1 090.68±15.14a | 25.93±0.27a | 12.18±0.22 |
| 18 Gy组 | 1 140.53±24.67a | 26.92±0.94a | 12.66±0.32a |
| 0 Gy+SP组 | 1 100.65±29.08a | 19.77±0.34a | 12.23±0.22 |
| 2 Gy+SP组 | 1 174.97±21.75b | 20.34±0.34b | 12.83±0.30 |
| 6 Gy+SP组 | 1 065.30±40.36c | 25.33±0.34 | 11.85±0.21 |
| 12 Gy+SP组 | 1 285.55±21.81d | 22.42±0.22d | 13.09±0.18d |
| 18 Gy+SP组 | 1 317.28±26.13e | 27.64±0.36 | 14.78±0.21e |
| F | 112.077** | 114.822** | 36.113** |
| [1] | 何秀娟, 林燕, 刘青武, 等. 皮肤成纤维细胞在创面愈合中的研究进展[J]. 中华损伤与修复杂志(电子版), 2021, 16(1):74-77. |
| HE X J, LIN Y, LIU Q W, et al. Research progress of skin fibroblasts in wound healing[J]. Chin J Injury Repair and Wound Healing, 2021, 16(1):74-77. doi: 10.3877/cma.j.issn.1673-9450.2021.01.015. | |
| [2] | 曾令军, 王文军, 李雪森, 等. P物质对人胚肺成纤维细胞作用及机制[J]. 中国公共卫生, 2021, 37(5):849-852. |
| ZENG L J, WANG W J, LI X S, et al. Effect of substance P on human embryo lung fibroblasts MRC-5 and its mechanism[J]. Chin J Public Health, 2021, 37(5):849-852. doi: 10.11847/zgggws1127521-new. | |
| [3] | FU H D, WANG S, GE B, et al. Nerve growth factor and substance P may be involved in moist exposed burn ointment-mediated chronic refractory wound healing[J]. Exp Ther Med, 2018, 16(3):1987-1993. doi: 10.3892/etm.2018.6390. |
| [4] | JUNG N, YU J, UM J, et al. Substance P modulates properties of normal and diabetic dermal fibroblasts[J]. Tissue Eng Regen Med, 2016, 13(2):155-161. doi: 10.1007/s13770-016-9085-2. |
| [5] | STUNOVA A, VISTEJNOVA L. Dermal fibroblasts-A heterogeneous population with regulatory function in wound healing[J]. Cytokine Growth Factor Rev, 2018, 39:137-150. doi: 10.1016/j.cytogfr.2018.01.003. |
| [6] | 蒋伟, 王正国, 赖西南, 等. P物质对肉芽组织成纤维细胞bFGF表达的调控作用及意义[J]. 中华烧伤杂志, 2003, 19(3):159-162. |
| JIANG W, WANG Z G, LAI X N, et al. Regulative effects and significance of substance P on the expression of basic fibroblast growth factor of granulation tissue fibroblasts in vitro[J]. Chin J Burns, 2003, 19(3):159-162. doi: 10.3760/cma.j.issn.1009-2587.2003.03.010. | |
| [7] | SALO P, BRAY R, SEERATTAN R, et al. Neuropeptides regulate expression of matrix molecule, growth factor and inflammatory mediator mRNA in explants of normal and healing medial collateral ligament[J]. Regul Pept, 2007, 142(1/2):1-6. doi: 10.1016/j.regpep.2007.01.001. |
| [8] | BAINBRIDGE P. Wound healing and the role of fibroblasts[J]. J Wound Care, 2013, 22(8):407-408,410-412. doi: 10.12968/jowc.2013.22.8.407. |
| [9] | CAKIN M C, OZDEMIR B, KAYA-DAGISTANLI F, et al. Evaluation of the in vivo wound healing potential of the lipid fraction from activated platelet-rich plasma[J]. Platelets, 2020, 31(4):513-520. doi: 10.1080/09537104.2019.1663805. |
| [10] | 何秀娟, 马慧可, 刘青武, 等. 细胞因子在创面修复中的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(5):579-585. |
| HE X J, MA H K, LIU Q W, et al. Research progress of cytokines in wound healing[J]. Chin J Clin Pharmacol Ther, 2021, 26(5):579-585. doi: 10.12092/j.issn.1009-250.2021.05.015. | |
| [11] | TONNESEN M G, FENG X, CLARK R A. Angiogenesis in wound healing[J]. J Investig Dermatol Symp Proc, 2000, 5(1):40-46. doi: 10.1046/j.1087-0024.2000.00014.x. |
| [12] | KOMI D, KHOMTCHOUK K, SANTA M P. A review of the contribution of mast cells in wound healing:Involved molecular and cellular mechanisms[J]. Clin Rev Allergy Immunol, 2020, 58(3):298-312. doi: 10.1007/s12016-019-08729-w. |
| [13] | KANT V, GOPAL A, KUMAR D, et al. Topically applied substance P enhanced healing of open excision wound in rats[J]. Eur J Pharmacol, 2013,g 715(1/2/3):345-353. doi: 10.1016/j.ejphar.2013.04.042. |
| [1] | XIE Pengliang, ZHENG Lufang, LI Yan, ZHENG Yanjin, BAI Lingdi, ZHAO Xia, LU Yinglong. Correlation of vascular endothelial growth factor with the severity of cystoid macular edema in patients with diabetes mellitus [J]. Tianjin Medical Journal, 2025, 53(9): 927-931. |
| [2] | ZHU Fangfang, LI Shida, CHEN Xiuying. The therapeutic effect of Dangui Quyu Pill combined with acupuncture on adenomyosis [J]. Tianjin Medical Journal, 2025, 53(7): 765-769. |
| [3] | DU Lingyun, WANG Yaowu, REN Nan. Prognostic value of PRMT2, TRAF2 and metastasis-related gene in renal clear cell carcinoma [J]. Tianjin Medical Journal, 2025, 53(5): 492-497. |
| [4] | WANG Linna, WANG Di, DONG Yanhong. Clinical effect of aribulin combined with NP regimen in the treatment of patients with advanced breast cancer [J]. Tianjin Medical Journal, 2025, 53(3): 326-330. |
| [5] | GAO Pan, XIE Bingxin, ZHOU Zandong, LIU Tong. Promoting effect of circulating FGF23 on atrial fibrosis in chronic kidney disease [J]. Tianjin Medical Journal, 2024, 52(9): 917-923. |
| [6] | LUO Kun, WANG Zhi, WANG Ke. Impacts of alpinetin on angiogenesis in knee osteoarthritis rats by regulating the VEGF/SphK1/S1P signaling pathway [J]. Tianjin Medical Journal, 2024, 52(5): 480-485. |
| [7] | MAN Jun, GAO Yanyan, SONG Longfei, GAO Fusheng. The effect of lncRNA FEZF1-AS1 targeting regulation of miR-200c-3p on biological behaviors of human lung fibroblasts [J]. Tianjin Medical Journal, 2024, 52(3): 231-236. |
| [8] | LIU Dan, TANG Zhanying, LI Pan, YUAN Weina, LI Fangfang, CHEN Qian, HU Zhijun. Effect of Yiqi Huoxue Tongluo Decoction on miR-126a-5p and VEGF signaling pathway in cervical spondylotic myelopathy model rats [J]. Tianjin Medical Journal, 2024, 52(3): 273-277. |
| [9] | ZHENG Yaru, HUANG Yibin, SU Xiaoping, ZHANG Yanjun. Effects of quercetin on periodontal tissue angiogenesis during orthodontic tooth movement in rats by regulating HIF-1α/VEGF signaling pathway [J]. Tianjin Medical Journal, 2024, 52(12): 1251-1255. |
| [10] | LIU Haoying, SHI Tianwei. Progress of the aryl hydrocarbon receptor in inflammatory skin diseases [J]. Tianjin Medical Journal, 2024, 52(11): 1221-1225. |
| [11] | HOU Yongbo, YU Junma, ZHU Haijuan. New research progress of exosomes in the treatment of myocardial infarction [J]. Tianjin Medical Journal, 2023, 51(9): 1016-1019. |
| [12] | SUI Yuan, ZHANG Chengsen, WANG Shuang, LI Xueli, GOU Xiaomei. Correlation analysis of circRNA-ZNF532 and circRNA-HIPK3 with diabetic retinopathy [J]. Tianjin Medical Journal, 2023, 51(9): 993-997. |
| [13] | QIN Zongbi, XU Aiqin, CAI Xiang, QIU Baiyi, WANG Shoufan, LI Linghua, ZHU Lihong. Effects of berberine on skin damage in rats with chronic eczema by regulating PI3K/AKT/NF-κB signaling pathway [J]. Tianjin Medical Journal, 2023, 51(8): 834-840. |
| [14] | ZHU Yuting, YAN Wen, YING Lisheng, WANG Jinjing. Effects of tetramethylpyrazine on expression levels of TNF-α, IL-17 and VEGF in skin lesions of psoriatic mice [J]. Tianjin Medical Journal, 2023, 51(6): 590-595. |
| [15] | HAN Zhenyan, GUAN Hongqiong. The expression profile of circular RNA in placenta of patients with preeclampsia and its correlation with the patient’s condition [J]. Tianjin Medical Journal, 2023, 51(5): 513-517. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||